Immunogenicity of recombinant adenoviral (Ad) vectors severely hampers the clinical development of gene therapy protocols using repeated vector administrations. Inhibition of costimulation by APCs was explored as a strategy to circumvent the immune response against Ad particles. This strategy was tested in rhesus monkeys, treated transiently with chimeric anti-human CD40 and anti-human CD86 antagonist monoclonal antibodies (MAbs) at the time of systemic administration of a recombinant Ad vector. After Ad vector administration in the absence of immunosuppressive treatment, transgene expression in the serum lasted about 3-4 weeks. All control animals developed a strong neutralizing antibody (NAb) response to the Ad particles, which totally prevented efficient administration of a second vector, as shown by the lack of transgene expression. Treatment with anti-CD40 and anti-CD86 chimeric MAbs delayed or blocked the development of a humoral response against Ad and the infiltration of CD8 þ lymphocytes into the liver. This resulted in (i) increased persistence of Ad-transduced cells after injection of a first vector encoding a nonimmunogenic transgene, and (ii) the possibility of readministering a second Ad vector with significant efficacy. In both respects, the combined blockade of CD40 and CD86 was more efficient than treatment with anti-CD40 alone. This study shows for the first time in non-human primates that blocking CD40 and CD86 costimulatory molecules represents a promising strategy to inhibit immune responses against an Ad vector injected systemically.
Introduction
Gene therapy is generally accepted as a promising technology for the treatment of a variety of inherited deficiencies and for the delivery of vaccinal genes or biological therapeutic drugs. However, in the last few years, it has become increasingly clear that adenovirus (Ad) vectors may have limited therapeutic value for chronic diseases, due to the development of a strong immune response to Ad particles. [1] [2] [3] [4] [9] [10] [11] [12] Firstly, the expression of the transgene is only transient, which has been explained by the elimination of transduced tissues by inflammatory processes and a cell-mediated immune response directed against the Ad vector and/or the transgene. 5, 8, [11] [12] [13] Secondly, the humoral response generated against the Ad particles represents the major obstacle to the repeated use of Ad vectors, resulting in poor (or no) transduction efficiency upon readministration. 3, [7] [8] [9] [10] [11] [12] 14 Since the neutralizing antibody (NAb) response is induced by the injected virus particles, 5, 15 further genetic modification or deletion of the Ad vector is unlikely to abolish immunogenicity. Given the inability of the Ad vector to replicate and the short persistence of the virus particles in the circulation, a transient blockade of the immune response may prevent the formation of NAbs and allow vector readministration. This would greatly improve the perspectives of Ad-mediated gene therapy for the long-term treatment of genetic diseases.
A large body of evidence suggests that transient blockade of APC-T-cell costimulation represents a promising strategy. CD40-CD40L and CD28-CD80/86 interactions are the two major costimulatory pathways required for amplifying antigen-specific immune responses including both T-cell and APC functions. 16, 17 CD40L/CD154 is transiently induced on T cells upon antigen recognition. CD40L stimulation of CD40 molecules, present on the surface of B cells, plays a crucial role in the development of the humoral response, including immunoglobulin (Ig) isotype switching and regulation of B-cell proliferation. In addition, activation of APCs, notably of dendritic cells and macrophages, through CD40 results in increased expression of CD80 and CD86 costimulatory molecules. CD28 is the T-cell counterreceptor for CD80/CD86, and its binding positively stimulates lymphocyte activation.
Evidence that blockade of the signals provided by the CD28-CD80/86 and/or CD40-CD40L costimulatory pathways can enhance the persistence of transgene expression in vivo is provided by several studies. Shortterm immunosuppression using murine CTLA4-Ig resulted in prolongation of transgene expression, but was unable to inhibit the formation of Ad-specific NAbs. 18 Mice deficient for CD40L showed improved persistence of transgene expression both in the liver and lung tissues, and the formation of anti-Ad NAb was diminished in mice treated with anti-CD40L. 19 Cellular and humoral reponses against Ad were partially inhibited by treatment with anti-CD40L monoclonal antibody (MAb), which allowed vector readministration to the lungs of mice. 20 However, blocking the CD40-CD40L pathway in mice was not sufficient to inhibit the immune response and to allow readministration by the systemic route. 19, 22 In non-human primates, treatment with anti-CD40L blocked both the production of anti-Ad NAbs and Ad-specific lymphoproliferative responses after vector instillation in the lung. 21 The combined blockade of both costimulatory pathways using CTLA4-Ig and an anti-CD40L MAb in mice resulted in increased persistence of first transgene expression, and was necessary to allow effective secondary Ad-mediated gene transfer through the systemic route. 22 Recently, we studied the respective roles of CD80 and CD86 in the immune response against Ad, using antagonist anti-CD80 or anti-CD86 MAbs in combination with anti-CD40L in mice. 23 We observed that the simultaneous blockade of these three molecules upon first vector administration allowed optimal expression of the transgene after a second vector administration. 23 This prompted us to design an experiment in a nonhuman primate model, to verify whether transient costimulation blockade could facilitate readministration of an Ad vector through the systemic route. The interaction between monkey CD40 and CD40L was targeted at the APC side using an antagonist anti-human CD40 MAb, 5D12. This MAb, either in its chimeric form (ch5D12) 24 or as parent murine MAb (mu5D12) 25 was shown to successfully protect from EAE in a non-human primate model, and proved to be safe in cynomolgus monkeys. 26 The anti-human CD86 MAb Fun-1 has not been widely used in non-human primate animal models. However, the efficacy of this MAb in combination with anti-human CD40 has been shown recently in a rhesus monkey kidney transplantation study. 27 The present study demonstrates the functional in vivo activity of ch5D12 and chFun-1 MAbs in a rhesus monkey model of systemic transduction with an Ad vector, for preventing the immune response against the gene therapy vehicle. These results are encouraging as they confirm that it is feasible to block the humoral response induced by systemic injection of an Ad vector, allowing readministration of the vector.
Results

Repeat systemic injection of Ad vector in immunocompetent rhesus monkeys
Animals were selected to be included in the study on the basis of the absence of NAbs against Ad in the serum. As control experiment (Figure 1, upper panel) , two animals were first injected intravenously either with Ad-hsCD4 (monkeys C and D) or with Ad-mgIFN (monkeys A and B) at the dose of 5 Â 10 10 infectious units (i.u.)/kg. No adverse toxic effects were observed after injection. Only around 10 days following administration, liver transaminases transiently increased in monkey B. High amounts of the transgene products were found in the serum samples following this first administration ( Figure  2 ): levels of mgIFN reached 5.7 g/ml (A) and 14.9 mg/ml (B), while hsCD4 peaked at 9.4 mg/ml (C) and 6.8 mg/ml (D). The kinetics of expression were different depending on the vector used, with a delayed appearance but a better persistence of hsCD4, which peaked at day 14 and could be detected until day 32 postadministration (date of readministration). MgIFN reached its highest level at day 3 and was rapidly cleared; only traces were detected at days 25 or 29. These differences in the kinetics might be explained by a better immunological tolerance to the : monkeys E and F were treated with MAb anti-CD40 (ch5D12) alone. Animals G and H received a combination of anti-CD40 and anti-CD86 (chFun-1) at days -3, 0 and þ 3 relative to the first vector administration. Ad-hsCD4 was the first vector injected, using doses of 5 Â 10 10 i.u./kg for E, F and G, and of 1.8 Â 10 10 i.u./kg for H. All the four monkeys were readministered 5 Â 10 10 i.u./kg of Ad-mgIFN at day 32, in the absence of costimulation-blocking treatment. Transgene products hsCD4 and mgIFN were titrated in the serum along the experiments. The humoral responses against the Ad vector and the transgenes, the serum levels of costimulation-blocking MAbs and the anti-MAb humoral responses were measured. At the end of the experiments (between days 64 and 71), animals were autopsied and livers were analysed by immunohistochemistry for the presence of immune cell types.
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H Haegel-Kronenberger et al human transgene (soluble CD4) as compared to the mouse one (gIFN), which is supported by the high homology between rhesus monkey and human CD4 (about 95%) and Igs. This was investigated and, indeed, we found that while monkeys A and B mounted a rapid humoral response against mgIFN (data not shown), antihsCD4 Abs were never detected using various ELISA strategies. We therefore concluded that rhesus monkeys are tolerant to transgene hsCD4 but not to mgIFN. A strong and rapid humoral response against Ad followed the first vector administration in all animals. At 3 days before readministration, high NAb titers (420 000) were observed in all animals ( Figure 3a) . The same dose of the alternative vector was chosen for the second intravenous injection at day 32. As expected, readministration revealed totally inefficient and not even traces of the transgene products were detected in the serum samples obtained after the second Ad administration (Figure 2 ), NAbs against Ad having prevented retransduction of the targeted tissues.
Antagonizing CD40 and CD86 improves transgene persistence
We have then tested the effect of antagonist MAbs antihuman CD40 (ch5D12) and anti-human CD86 (chFun-1) in this gene-transfer setting. Both MAbs were used in their chimeric version, in which the murine variable domains were placed on a human IgG 4 backbone. AdhsCD4 was chosen as the first vector to be injected in all four animals of the test group (Figure 1, lower panel) for the following two reasons: (i) results obtained from the control group suggested that the toxicity of Ad-mgIFN was higher than that of Ad-hsCD4, evidenced by a short increase in liver transaminases in one monkey; (ii) the transgene hsCD4 was found nonimmunogenic in rhesus monkeys and, therefore, the persistence of hsCD4 in the serum closely reflects the persistence of Ad-transduced cells. The dose of 5 Â 10 10 i.u./kg was conserved, with the exception of monkey H in the experimental group, which received a three-fold lower dose of Ad-hsCD4 (1.8 Â 10 10 i.u./kg). Two animals were treated with chimeric anti-CD40 MAb (ch5D12) alone, and two other animals with a combination of ch5D12 and chimeric anti-CD86 MAb (chFun-1).
In all the four monkeys, expression of the first transgene hsCD4 was prolonged until after day 35 ( Figure 4 ). The two animals treated with anti-CD40 showed detectable hsCD4 in the serum until day 43 and day 39, respectively ( Figure 4 , animals E and F). The increased persistence was even more striking in monkeys that received the combination of anti-CD40 and anti-CD86 (Figure 4 , animals G and H). Traces of hsCD4 (above 1 ng/ml) were still found in their serum at day 60. These results suggest that antagonizing costimulation inhibited a cell-mediated immune response against transduced cells, which was responsible for the disappearance of the hsCD4 transgene product around day 35 in the untreated monkeys.
Antagonizing CD40 and CD86 inhibits the humoral response against Ad Analysis of the humoral response against Ad following the first administration in the presence of anti-CD40 and anti-CD86 showed a clear decrease in anti-Ad NAb titers compared to the control monkeys (Figure 3a) . Titers remained very low until days 18-21, particularly in Figure 2 Repeated systemic injection of Ad vectors in control monkeys: inefficacy of readministration. The transgene products hsCD4 and mgIFN were titrated in the serum along the experiments. The kinetics of hsCD4 and mgIFN expression are shown for each monkey of the control group. Detection levels were above 1 ng/ml for hsCD4 and 0.1 pg/ml for mgIFN. Expression of the second transgene mgIFN (for C, D) or hsCD4 (for A, B) was never detected following readministration at day 32.
Systemic readministration of Ad vector in primates H Haegel-Kronenberger et al monkey F treated with anti-CD40 and in monkey H treated with the combination of anti-CD40 plus anti-CD86, the latter showing a total lack of NAbs at day 32, the time of vector readministration ( Figure 3a ). Again, it should be noted that monkey H, which received a threefold lower dose of vector, appeared to respond optimally to the immunosuppressive treatment. This suggests that the immune response induced by a lower antigen dose can be suppressed more easily than that induced by a high dose. In animals receiving a high vector dose, adenoviral antigens may not have been cleared completely from the circulation at the end of the costimulation-blocking treatment. The dose of the vector may be optimized to obtain sufficient transgene expression with lower immune stimulation.
Serum levels of the antagonist MAbs were measured along the experiment, as well as the humoral response developed against these MAbs in each monkey (rhesus antichimeric antibody (RACA) response). It was observed that in each group (treated with anti-CD40 alone or with anti-CD40 þ anti-CD86), one animal cleared the MAbs relatively slowly compared to the other animal in . These animals had therefore a longer period of functional inhibition of costimulation, and they were those showing the most efficient repression of the humoral response against Ad (monkeys F and H, see Figure 3a ). After clearance of the MAbs from the circulation, a humoral anti-MAb response was observed ( Figure 5 ). Again, the animals characterized by a longer persistence of the MAbs in the serum subsequently developed lower levels of Abs against these MAbs. These observations suggest that a longer duration of costimulation blockade may be able to completely prevent a humoral immune response.
Immune response to Ad vector readministered in the absence of costimulation blockade
To better characterize the humoral response in the treated animals, the IgM/IgG isotypes of anti-Ad Abs were quantified by ELISA ( Figure 3b ). In control monkeys and in the MAb-treated animals that developed a humoral response before readministration, IgMs were generally predominant before day 25 and then decreased or remained stable. The switch from IgM to IgG was apparent at around day 25 in these animals. After readministration, anti-Ad IgG levels were further increased above the IgM. In monkey H, first injected with a lower dose of vector and treated with anti-CD40 and anti-CD86, no Abs against Ad were detected at the time of readministration; the anti-Ad NAb titer rose between 3 and 7 days post-readministration, as observed in untreated animals after the first administration of Ad vector (Figure 3a) . These results clearly show that the suppression of the humoral response against Ad by treatment with anti-CD40 and anti-CD86 was only transient in this animal, and that the capacity to respond to Ad had been restored 1 month following treatment. In this animal, that did not develop a significant humoral response after the first vector injection, a burst in IgM was observed after readministration in the absence of blocking MAb treatment ( Figure 3b , lower right panel). This reflected a primary type of humoral response, suggesting that B cells in this animal had not been primed by the first vector injection. Additionally, this suggests that the interactions mediated by CD40 and CD86 are necessary for the initiation of a humoral response against Ad in rhesus monkeys.
Antagonizing CD40 and CD86 facilitates Ad vector readministration
Following readministration at day 32, mgIFN expression was detected in the serum of all monkeys treated with either anti-CD40 or the combination of anti-CD40 þ anti-CD86 MAbs ( Figure 6 ). In animals E and F treated with anti-CD40 alone, however, mgIFN could be detected only in trace amounts (less than 10 pg/ml, Figure 6a ). In contrast, monkeys G and H treated with both anti-CD40 and anti-CD86 showed significant expression of the second transgene (Figure 6b ). Expression of mgIFN reached 300 pg/ml in monkey G and up to 33.6 ng/ml Systemic readministration of Ad vector in primates H Haegel-Kronenberger et al of this second transgene product was found in the serum of monkey H at day 39. These levels of serum mgIFN are respectively around 2-log and 5-log higher than those found in the animals treated with anti-CD40 only. The best efficiency of readministration was observed in monkey H, which received a lower dose of the first vector and developed the lowest anti-Ad humoral response with lack of NAbs before day 32. Still, in this animal, the peak level of mgIFN was approximately 2 logs lower than that found in the two control naïve monkeys A and B injected with the same dose of Ad-mgIFN ( Figure 2 ).
Costimulation blockade reduces liver infiltration by CD8 þ T cells
Liver and lungs are the main target organs transduced by Ad vectors injected systemically. Liver samples were taken at day 70 after the first injection to try to detect infiltrates of immune cell types. CD4 þ cells were only rarely detected and their numbers were not different between the livers of treated versus untreated animals. CD8 þ cells were not detected in a control liver from an untreated rhesus monkey (Figure 7a ) and small clusters of CD8 þ cells were only rarely detected in the liver from a monkey treated by lung aerosolization of Ad vector (Figure 7b ). In contrast, numerous clusters and infiltrates of CD8 þ T lymphocytes were found in the livers of all four animals injected with Ad vectors in the absence of costimulation blockade (Figure 7c, d) . These CD8 þ cells were found to be also CD3 þ (data not shown), indicative of a cytotoxic T lymphocyte (CTL) phenotype. The frequency and size of CD8 þ cell clusters were reduced in the liver sections from the monkeys treated with anti-CD40 at the time of first vector injection (Figure 7e, f) . This reduction was even more striking in the animals treated with both anti-CD40 and anti-CD86, as only rare CD8 þ cell clusters were localized around blood vessels (Figure 7g, h) . These results show that costimulation blockade inhibits the infiltration of CD8 þ T cells in the liver, and that antagonizing both CD40 and CD86 is more effective in this respect as compared to CD40 alone.
Discussion
This study shows for the first time in non-human primates that antagonizing CD40 and CD86 costimulatory molecules represents a promising strategy to inhibit immune responses against an Ad vector injected systemically. In our system, treatment with anti-CD40 and anti-CD86 chimeric MAbs delayed or blocked the development of a humoral response against Ad and the infiltration of CD8 þ lymphocytes into the liver. This resulted in (i) increased persistence of Ad-transduced cells after injection of a first vector encoding a nonimmunogenic transgene, and (ii) the possibility to readminister a second Ad vector encoding a different transgene with significant efficacy. In both respects, the combined blockade of CD40 and CD86 was more efficient than treatment with anti-CD40 alone.
Previous experiments performed in non-human primates have shown that transduction of the liver through systemic or intraportal administration of Ad vectors is 
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H Haegel-Kronenberger et al inflammatory but well tolerated, at least below a threshold dose. [5] [6] [7] During our experiments, adverse toxic effects were not detected in any of the monkeys, except for a short increase in liver transaminases in animal B around 10 days after injection of Ad-mgIFN. It was envisaged that this toxicity could be linked to the use of mouse transgene mgIFN, a molecule that was reported to be biologically inactive in primates. 28 A strong humoral response against mgIFN was detected in both injected animals, which could contribute to the observed toxicity through the formation of immune complexes, given the high amounts of transgene present in the serum at that time. Treatment with the chimeric anti-CD40 and anti-CD86 MAbs upon injection of Ad-hsCD4 was well tolerated in the four animals tested.
In mouse models, expression of nonimmunogenic transgenes can be relatively stable and long-lasting, suggesting that anti-Ad CTLs may play only a minor role in the elimination of transduced cells. [11] [12] [13] It was observed that administration of Ad vectors encoding murine erythropoietin resulted in stable expression in mice, as evidenced by long-term elevation of the haematocrite levels. 13 When murine erythropoietin was replaced by human erythropoietin cDNA, a strong 29 These studies point out the difference between immunological responses observed in murine compared to non-human primate models, the latter being more relevant for applications in humans. In rhesus monkeys, the persistence of expression of an immunogenic transgene, lacZ, was shown to be prolonged in the liver following treatment with cyclophosphamide/prednisone. 4 In a recent study, rhesus monkeys administered by the intratracheal route had diminished lymphoproliferative responses against Ad following treatment with a humanized blocking mAb against CD40L. 21 In our study, disappearance of first transgene hsCD4 from the serum of control monkeys correlated with the time of vector readministration. This suggested that a recall cellular response against Ad might be stimulated upon readministration, provoking the destruction of pre-existing Ad-transduced cells. In monkeys first treated with anti-CD40, persistence of expression of the first transgene hsCD4 was prolonged until after readministration. This increase in persistence became even more dramatic when both CD40 and CD86 were blocked, which resulted in detectable levels of hsCD4 at day 60. Since hsCD4 is nonimmunogenic in rhesus monkeys, our results suggest that the CTL response against Ad was downmodulated by costimulation blockade, thereby inhibiting the destruction of Adtransduced cells. The CTL response appears to be more efficiently suppressed using both anti-CD40 and anti-CD86 rather than anti-CD40 alone. This correlates with our results obtained in mice, showing that blocking CD86 in addition to CD40 more profoundly affects the cell-mediated immune response to Ad vector injection. 23 It should be noted that the best stability in the serum levels of hsCD4 was observed in the monkey, which received a three-fold lower dose of vector at the first injection (monkey H). As expected, this animal showed an initial level of transgene expression lower than the three other animals, but in contrast the highest level of expression at day 50, suggesting that a better persistence may be achieved using moderate rather than very high doses of vector in this experimental design.
The vast majority of T cells infiltrating the liver, 1 month after Ad vector readministration, were CD8
þ . The density of infiltrating CD8 þ T cells was reduced in the livers of animals previously treated with anti-CD40, and this reduction was more pronounced in the livers of animals treated with both anti-CD40 and anti-CD86. Only few CD4 þ cells were detected in the organ at that time. Interestingly, it has been shown that treatment of rhesus monkeys with a nondepleting anti-CD4 MAb was ineffective in downregulating the immune response against Ad injected in the lungs, and therefore did not permit secondary Ad-mediated gene transfer.
14 This is in contrast with the situation observed in the mouse, as treatment of human CD4-transgenic mice with the same MAb allowed Ad vector readministration in the lungs. 30 These results suggest that the cellular immune response against recombinant Ad vectors may be mainly mediated by CD8 þ T cells in rhesus monkeys, again illustrating the difference between mouse models and non-human primate models.
While readministration of Ad vectors was totally ineffective in all control animals, all the animals treated with anti-CD40 with or without anti-CD86 showed expression of the second transgene mgIFN to various extents. As expected, the efficiency of readministration was inversely correlated with the pre-existing humoral immunity to the Ad vector. Total anti-Ad Abs were decreased in the four treated monkeys at day 32, the time of readministration. Again, the best results were obtained in animal H treated with both anti-CD40 and anti-CD86. This monkey did not develop anti-Ad NAbs before readministration at day 32, and the level of second transgene product in its serum was only 2-log lower than that observed in naïve animals injected for the first time.
Nunes et al 7 have demonstrated that the efficiency of readministration was inversely correlated with the initial dose of Ad vector injected in monkey liver. However, in this study, the initial vector dosage that did not inhibit retransduction of the liver was not sufficient to support detectable transgene expression; this suggests that the use of a powerful expression cassette may be necessary to obtain the required levels of transgene product and lower the dose of viral vector. Our results suggest that optimization of both vector dosage and the costimulation-blocking treatment may allow to achieve stable and long-term expression of a transgene, provided that its product is not immunogenic.
Although monkey H had no detectable anti-Ad NAbs in the serum before vector readministration, the level of expression of the second transgene was still 2-log lower than in control naïve animals A and B injected first with Ad-mgIFN. This might be explained by an increased destruction of Ad-transduced cells upon reinjection, due to an incomplete inhibition of the cell-mediated immune response by costimulation blockade. In addition, it is worth noting that the amounts of anti-Ad Abs did not differ significantly between monkeys G and E, which does not correlate with the difference in serum mgIFN found after readministration: monkey G treated with both MAbs showed a 2-log higher mgIFN peak level at day 3 0 , as compared to monkey E treated with anti-CD40 alone. This indicates that besides reducing the humoral response, treatment with both MAbs has other beneficial effects compared to anti-CD40 alone. More efficient downregulation of the CTL response by both anti-CD40 and anti-CD86 MAbs, as suggested above, stands as a likely explanation for this observation.
Antigen presentation in the absence of costimulation may induce tolerance. 31, 32 Monkeys treated with anti-CD40 with or without anti-CD86 did not develop tolerance to the Ad vector, as the humoral response against Ad was strongly stimulated following vector readministration in the absence of costimulation-blocking treatment. This was not a surprise, since, in this experimental setting, other key molecules such as CD80 on APCs remain available for the costimulation of T-cell responses. In addition, our results obtained in mice have shown normal humoral and cellular responses to Ad readministration even in mice previously treated with anti-CD40L, anti-CD80 and anti-CD86 blocking MAbs upon first vector injection. 23 Systemic
A common observation between mouse and primate models is that the simultaneous blockade of CD40-CD40L interaction and CD86 is much more efficient in blocking the humoral and cellular response against Ad than blockade of CD40-CD40L alone. By blocking both CD40L and CD86 in the mouse, we have observed expression levels of a second transgene after readministration, only one half-log lower than those found in naive animals after a first vector injection. 23 However, optimal results were obtained only when mice were simultaneously treated with the three costimulationblocking MAbs anti-CD40L, anti-CD80 and anti-CD86; in this situation, the humoral and cellular immune responses were practically undetectable, and expression levels of the second transgene were similar to those observed in naive animals. It is probable that, in nonhuman primates, blockade of CD80 in addition to CD40 and CD86 would be necessary to inhibit more drastically the development of the immune response against Ad, thereby allowing vector readministration with maximal efficacy. Moreover, optimization of both the vector dosage and the costimulation-blocking treatment may render the use of Ad vectors possible for repeat administrations through the systemic route.
Materials and methods
Animals
The study was carried out in rhesus monkeys (Macaca Mulatta). The animals met the following criteria: They were between 4 and 7 years of age, in good health, showed normal values for haematology and clinical chemistry. They were screened for the absence of Abs directed against Ad and for the lack of serum reactivity in ELISA for the detection of transgene expression. The animals in the experimental group ( Figure 1) were also screened for the absence of Abs directed against the chimeric anti-CD40 and anti-CD86 MAbs. During the experiment, the animals (males or females) were housed separately in a D-2 facility. Individual animals were identified by a number combination tattooed on the chest. The housing room was environmentally controlled for temperature (21-231C). The rhesus monkeys were offered a daily diet consisting of monkey chow (Hope Farms, Woerden, The Netherlands), supplemented by fresh fruit, vegetables and bread. Drinking water was available ad libidum via an automatic watering system. Historical medical records of the rhesus monkeys were retained as part of the study records.
Recombinant Ad vectors
Ad vectors were constructed at Transgene. They were derived from Ad serotype 5, first as infectious plasmids obtained by homologous recombination in Escherichia coli, 32 and subsequently deleted of viral E1 and E3 regions. Expression cassettes were inserted in place of the E1 region, in sense orientation. AdTG13048 (AdmgIFN) contained the cDNA of murine gIFN under the control of the human CMV promoter and followed by a SV40 polyadenylation signal, with a bglobin/IgG chimeric intron. AdTG8357 (Ad-hsCD4, human soluble CD4) encoded a gene composed of the v1 and v2 domains of human CD4 fused to the Fc region of a human IgG, preceded by the RSV promoter and a b-globin intron and followed by a b-globin polyadenylation signal. For the generation of viruses, the viral genomes were released from the respective recombinant plasmids by PacI digestion and transfected into 293 cells. 33 Virus propagation, purification and titration of the viral particles were carried out as described previously. 34, 35 For each virus preparation, the concentration of i.u. was measured by indirect immunofluorescence of the viral DNA-binding protein. 35 Purified virus was stored in viral storage buffer containing 1 M sucrose, 10 mM Tris-HCl (pH 8.5), 1 mM MgCl 2 , 150 mM NaCl and 0.005% Tween 80. The vectors were controlled for the absence of endotoxin contamination. They were stored at À801C and thawed once, just before usage.
Anti-CD40 and anti-CD86 blocking MAbs
The anti-human CD40 and anti-human CD86 chimeric MAbs comprise the variable domains from murine MAbs placed on a human IgG 4 backbone. The chimeric anti-CD40 MAb was labelled ch5D12 and the chimeric anti-CD86 MAb was labelled chFun1. Both Abs were stored at 41C.
Administration of Ad vectors and MAbs
The Ad vectors were administered intravenously and dosed over a period of about 10 min. Both groups received a first injection of Ad vector at day 0 and a second at day 32 ( Figure 1 ). In the control group, two animals received Ad-mgIFN at day 0 and Ad-hsCD4 at day 32 (5 Â 10 10 i.u./kg). The other two animals received the same doses of Ad-hsCD4 at day 0 and Ad-mgIFN at day 32. Ad-hsCD4 was chosen as the first vector to be injected in all the four animals of the experimental group. The dose of 5 Â 10 10 i.u./kg was conserved, with the exception of monkey H in the experimental group that received a three-fold lower dose of 1.8 Â 10 10 i.u./kg. The animals were dosed using an injection needle (Butterfly 21G, green, Luer) in the vena saphena.
The anti-CD40 and anti-CD86 chimeric MAbs, from PanGenetics B.V., were administered intravenously and dosed over a period of about 10 min. In the test group, two animals received a treatment of anti-CD40 alone and two animals received both anti-CD40 and anti-CD86 MAbs (Figure 1 ). MAbs were administered at day -3 (10 mg/kg/MAb), day 0 and day 3 (both 5 mg/kg/ MAb), relative to Ad vector injection. The animals were anaesthetized using ketamin before i.v. injection of the Ad vectors and of the MAbs.
Observations, analysis and measurements
At several time points during the experiment, blood samples (EDTA) were collected from the femoral vein in the groin using aseptic techniques: Vacutainer bloodcollection systems (Becton Dickinson, Vacutainer systems, France) were used. EDTA blood was taken for the haematology and FACS analysis. Clotted blood was taken for clinical chemistry and determination of serum levels of the transgenes, anti-Ad IgG and IgM, anti-Ad NAbs, anti-transgene Abs, serum levels of anti-CD40 and anti-CD86 MAbs and the anti-chimeric MAb response (RACA response) in the test group animals. Serum was collected by centrifugation of clotted blood, and stored at À801C until usage. Clinical chemistry. Serum was collected by centrifugation of clotted blood. The following determinations were performed on serum samples at the Laboratory Centre for Clinical Chemistry SSDZ, Delft, The Netherlands: sodium, potassium, chloride, bicarbonate, urea, creatinine, alkaline phosphatase, ASAT, ALAT, LDH, total bilirubine, gamma-GT, cholesterol, total protein and albumin.
Pathology and immunohistochemistry. Due to safety rules, all animals were killed at the end of the experiment (between days 64 and 71). The animals were weighed, and EDTA blood was taken for haematology and subset analysis in the test group animals. The animals underwent a complete necropsy in which the abdominal and thoracic cavities were opened. Tissues of interest were preserved in a neutral aqueous phosphate-buffered 4% solution of formaldehyde, and were also cryopreserved. Histopathological examination was performed on the following organs: liver, lungs, lymph nodes (axillary, inguinal) and spleen.
Liver cryosections were permeabilized with acetone and endogenous peroxidases were quenched in 1% H 2 O 2 . Sections were incubated with either mouse antihuman CD8 mAb (clone RPA-T8, BD Pharmingen 30321A, dilution 1/500) or rat anti-human CD4 (clone OKT4a) diluted in goat serum (G6767, Sigma, St Louis, MO, USA) for 2 h at room temperature. After washing in PBS containing 0.1% Tween (Sigma P5188), staining was revealed using the Envision peroxidase system for the revelation of rabbit or mouse Igs (K4001 and K4003, Dako) was used according to the manufacturer's instructions, with 3.3 diaminobenzidine (K3467, Dako) as chromogen. For staining of CD3-positive cells, sections were incubated with rabbit anti-human CD3 (A0452, Dako) diluted 1/200 and washed in PBS 0.01% Triton X-100 (Sigma) before revelation, using the Envision system for rabbit Igs (K4003, Dako).
Levels of anti-CD40 and anti-CD86 MAbs and RACA response. Prior to each administration of ch5D12 or chFun-1 and on various time points after the last administration, serum samples were prepared from venous blood to determine MAb levels and anti-MAb responses (RACA responses). ch5D12 and chFun-1 concentrations were determined in an ELISA assay. Briefly, the plates were coated with 100 ng/ml of either recombinant CD40-Fc for ch5D12 or CD86-Fc for chFun-1. A goat-anti-kappa light chain was used to detect the MAbs. To circumvent nonspecific binding in the ELISAs, the standard matrix contained 5% BSA. For quantification, triplicate standard serial dilutions of the MAbs (4000-40 ng/ml) were added onto each plate.
For the detection of Abs against the variable regions of ch5D12 or chFun-1, plates were coated with murine 5D12 or murine Fun-1 at a concentration of 2 mg/ml. An alkaline-phosphatase-labelled rabbit anti-monkey IgG antibody (Ab) was used for detection (Sigma Immunochemicals, St Louis, MO, USA). Rhesus monkey serum samples were serially (1:1) diluted from a start dilution of 1:100 to a final dilution of 1:12 800. Responses were scored positive for anti-ch5D12 or anti-chFun-1 variable region when the signal exceeded the background signal by a factor 2. Background was determined in prestudy serum samples of the animal at the same dilution on the same plate.
Measurement of transgene concentrations in serum.
Murine gIFN was titrated using the Quantikine ELISA kit from R&D Systems (Minneapolis, MN, Cat# MIF00) and hsCD4-2F5, using the soluble CD4-ELISA kit from Boehringer Mannheim Biochemica (Roche, Meylan, France, Cat# 1460 358).
Titration of IgG and IgM against Ad. ELISA 96-well plates (Nunc Immunosorpt, PolyLabo, Strasbourg, France) were coated with 3 Â 10 12 particles/ml of inactivated Adbgal in 0.2 M NaHCO 3 -0.08 M Na 2 CO 3 (pH 9.5) by overnight incubation at 41C under shaking. Plates were washed five times with PBS-0.1% Tween 20-10 mM EDTA, and saturated with 3% BSA in PBS for 1 h under agitation at room temperature. A volume of 100 ml/well of serum samples diluted in PBS-0.1% BSA (from 1/200 to 1/25 600) was incubated for 2 h at room temperature. The plates were washed five times before incubation for 1 h with HRP-conjugated antimonkey IgG or anti-monkey IgM (Rockland, Gilbertsville, PA, USA) and revelation in 1% TMB (3, 3 0 ,5,5 0 -tetramethylbenzidine, Sigma T-2885)-0.05 M Na acetate-0.1 M citric acid-0.015% H 2 O 2 . Reaction was stopped upon addition of 100 ml H 2 SO 4 and OD was read at 450 nm. along the following wells to obtain serum dilutions in the Adbgal suspension from 1/10 to 1/20 500 (or more). The serum and virus were incubated for 1 h at room temperature, before transfer onto the 293 cells at around 70% confluence. After 1 h at 371C, 100 ml of culture medium was added to the wells and the plates were further incubated for 14-18 h. The medium was aspirated and wells were washed twice gently with PBS before addition of 100 ml revelation solution (0.017% 4-methyl umbelliferyl b-D-galactoside (MUG, Sigma M1633), 5% Triton X-100 in 6 mM Na 2 HPO 4 , 4 mM NaH 2 PO 4 , 10 mM KCl, 0.1 mM MgSO 4 and 50 mM bmercaptoethanol). After 30 min incubation at 371C, OD was read at 340/460 nm. The background was calculated from wells containing only 293 cells and medium.
Maximal infection by Ad-bgal was defined from wells containing 293 cells and virus suspension in the absence of serum. NAb titer was defined as the inverse of the first serum dilution giving 50% or less inhibition of infection.
